Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InxMed Starts Pivotal Trial of FAK Inhibitor for Resistant Ovarian Cancer

publication date: Sep 8, 2022

Nanjing InxMed has started a pivotal China Phase II trial of its lead drug, a selective oral inhibitor of focal adhesion kinase (FAK), in patients with platinum-resistant recurrent ovarian cancer (PROC). InxMed develops innovative therapies that target drug resistance and metastasis in hard-to-treat solid tumors. The Phase II study will test IN10018 in combination with pegylated liposomal doxorubicin (PLD) in patients with PROC. At ASCO 2022, InxMed reported the combination regimen showed antitumor efficacy and a good safety profile in PROC patients. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital